Cargando…
FLT3 inhibitors: clinical potential in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%–40% of cases. Tremendous improvements in AML prognostication arose from a comprehensive analysis of leukemia cell genomes. Among normal karyotype AML cases, mutations in the FLT3 gene are the ones m...
Autores principales: | Hospital, Marie-Anne, Green, Alexa S, Maciel, Thiago T, Moura, Ivan C, Leung, Anskar Y, Bouscary, Didier, Tamburini, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304990/ https://www.ncbi.nlm.nih.gov/pubmed/28223820 http://dx.doi.org/10.2147/OTT.S103790 |
Ejemplares similares
-
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015) -
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
por: Chapuis, Nicolas, et al.
Publicado: (2019) -
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015) -
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020) -
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia
por: Meunier, Godelieve, et al.
Publicado: (2020)